Carfilzomib Works Well As Salvage Therapy; Momentum Builds For Frontline Role
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Onyx Pharmaceuticals, Inc. reported positive trial results from a Phase IIb study showing its oral proteasome inhibitor carfilzomib works well as a single salvage treatment for multiple myeloma, lending some support to the company’s plans to seek accelerated approval in this area of high unmet need.